LOGO.jpg
Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
October 14, 2020 06:30 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (Nasdaq: IDXG) announced today that the Audit Committee of the Board of Directors has...
Logo 1.png
Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 09, 2020 08:00 ET | Aeterna Zentaris Inc
- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT - CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:...
Logo 1.png
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
September 08, 2020 08:05 ET | Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
Logo 1.png
AETERNA ZENTARIS ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
August 03, 2020 09:00 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...
OmniPathology-Logo-Color-01.jpg
OmniPathology Releases New COVID-19 Testing for Greater Los Angeles
March 24, 2020 14:42 ET | OmniPathology
PASADENA, Calif., March 24, 2020 (GLOBE NEWSWIRE) -- OmniPathology today announced the launch of its COVID-19 Lab Developed Test LDT. In response to the US Food and Drug Administration (FDA) policy...
Logo.jpg
BioPorto Appoints New President of BioPorto Diagnostics, Inc.
April 15, 2019 09:00 ET | BioPorto A/S
Company Plans to Bring Novel Kidney Diagnostic to US Market Hellerup, Denmark, April 15, 2019 (GLOBE NEWSWIRE) -- Today, BioPorto A/S CPH: BIOPOR (“BioPorto”) announces the appointment of Amy...
DiamiR Announces $1.5M SBIR Phase II Funding for Further Evaluation of the microRNA Biomarkers for Early Detection of Alzheimer's Disease
March 16, 2015 08:02 ET | DiamiR
MONMOUTH JUNCTION, NJ--(Marketwired - March 16, 2015) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...
ARUP Laboratories Ad
ARUP Laboratories Adds Prosigna to Its Test Menu
March 05, 2014 13:34 ET | ARUP Laboratories
SALT LAKE CITY, March 5, 2014 (GLOBE NEWSWIRE) -- ARUP Laboratories announced on Monday, March 3, that it has added the Prosigna Breast Cancer Prognostic Gene Signature assay to its comprehensive...